Prostatectomy

Jelqing: the latest in a long history of attempts to enlarge the male member

Retrieved on: 
Thursday, February 15, 2024

Posts advise that stretching a semi-erect penis could add up to an inch in length and girth by exploiting the body’s repair mechanisms.

Key Points: 
  • Posts advise that stretching a semi-erect penis could add up to an inch in length and girth by exploiting the body’s repair mechanisms.
  • Jelqing is just the latest in a long line of dubious penis enlargement techniques stretching (sorry) back millennia.
  • The ancient Greek method of lengthening the foreskin with a kynodesme (dog leash) seems positively mild compared with ancient Indian methods.
  • Penis pumps are also used for erectile dysfunction, but unlike some online claims, they don’t lengthen the penis.

Surgical interventions

  • Fillers are increasing in popularity, particularly hyaluronic acid (HA) injections.
  • HA is popular because it is doesn’t generate an immune response.
  • Surgery to cut the suspensory ligament anchoring the penis is the most widely accepted surgical elongation method.
  • A recent review concluded that evidence for supporting surgical procedures for penis enlargement is weak and the complications are under-reported.

Not needed, in most cases

  • A micropenis, usually diagnosed at birth, is where the penis is 2.5 standard deviations less than the average stretched penis length (2.3 to 2.5cm depending on ethnicity).
  • It is typically caused by a deficiency or imbalance of hormones such as testosterone or human chorionic gonadotropin (hCG), or genetics.
  • The female vagina is on average 2.5 to 3.8 inches deep, but lengthens during sexual arousal to accommodate a penis longer than this.
  • The female genitalia have multiple erogenous structures that can result in orgasm, so penile length isn’t the key characteristic.

A closer look at jelqing

  • The top two consist of numerous spaces that are surrounded by smooth muscle, which keeps most blood out of the spaces.
  • During an erection, the muscles relax allowing blood to flow in, filling these spaces, and enlarging penile volume.
  • While the theory sounds good, smooth muscle cells in the penis don’t respond in the same way skeletal muscle does.
  • If jelqing, or any other trend, was really that effective, we would have seen evidence of it in medical journals, and the sale of extra-large underwear would be making the headlines.


Adam Taylor does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Global Surgical Robots Market Forecast Report to 2030 - Partner & Customer Ecosystem Competitive Index & Regional Footprints - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 24, 2024

The "Global Surgical Robots Market 2030 by Product Type, Application, End-user, and Region - Partner & Customer Ecosystem Competitive Index & Regional Footprints" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Surgical Robots Market 2030 by Product Type, Application, End-user, and Region - Partner & Customer Ecosystem Competitive Index & Regional Footprints" report has been added to ResearchAndMarkets.com's offering.
  • Major players Surgical Robots Market include: Stryker Corporation, Medrobotics, Smith & Nephew, TransEnterix Surgical, Inc., Renishaw plc., Intuitive Surgical, Medtronic, THINK Surgical, Inc., Zimmer Biomet, Asensus Surgical, Siemens Healthineers, CMR Surgical, Johnson & Johnson, Renishaw Plc.
  • The demand for these computer-assisted surgical systems is substantial, being utilized in open surgeries, laparoscopic procedures, and flexible endoscopic procedures.
  • One key trend in the Surgical Robots Market is the integration of artificial intelligence (AI) and machine learning (ML) technologies into surgical robotic systems.

CellVax Therapeutics Announces FDA Clearance of IND Application for FK-PC101, a Novel Personalized Cancer Immunotherapy

Retrieved on: 
Monday, January 29, 2024

FK-PC101 is CellVax's novel personalized cancer immunotherapy intended to treat prostate cancer patients who have a high risk of recurrence after prostatectomy.

Key Points: 
  • FK-PC101 is CellVax's novel personalized cancer immunotherapy intended to treat prostate cancer patients who have a high risk of recurrence after prostatectomy.
  • It consists of patient's own tumor cells which are collected during surgery, then modified in the laboratory.
  • Fernando Kreutz, CEO at CellVax, stated, "We are thrilled to receive FDA clearance of our FK-PC101 IND.
  • The trial, CELLVX-230, is a randomized, multicenter, open-label study of irradiated autologous cellular vaccine in men with high-risk prostate cancer post-radical prostatectomy.

Global Surgical Robots Market Report 2024 - Projected at USD 7.3 Billion by 2030: Integration of AI & High Demand for Minimally Invasive Surgeries Propel North America to the Forefront

Retrieved on: 
Wednesday, January 24, 2024

Major players Surgical Robots Market include: Stryker Corporation, Medrobotics, Smith & Nephew, TransEnterix Surgical, Inc., Renishaw plc., Intuitive Surgical, Medtronic, THINK Surgical, Inc., Zimmer Biomet, Asensus Surgical, Siemens Healthineers, CMR Surgical, Johnson & Johnson, Renishaw Plc.

Key Points: 
  • Major players Surgical Robots Market include: Stryker Corporation, Medrobotics, Smith & Nephew, TransEnterix Surgical, Inc., Renishaw plc., Intuitive Surgical, Medtronic, THINK Surgical, Inc., Zimmer Biomet, Asensus Surgical, Siemens Healthineers, CMR Surgical, Johnson & Johnson, Renishaw Plc.
  • The use of medical robotic systems has become widespread in the fields of gynaecology and cosmetology, particularly for minimally invasive surgeries.
  • The demand for these computer-assisted surgical systems is substantial, being utilized in open surgeries, laparoscopic procedures, and flexible endoscopic procedures.
  • One key trend in the Surgical Robots Market is the integration of artificial intelligence (AI) and machine learning (ML) technologies into surgical robotic systems.

Healthgrades Names 2024 America's Best Hospitals

Retrieved on: 
Tuesday, January 23, 2024

DENVER, Jan. 23, 2024 /PRNewswire/ -- Healthgrades , the #1 site Americans use to find a doctor or hospital, today announced the recipients of the 2024 America's Best Hospitals Awards and State Rankings.

Key Points: 
  • DENVER, Jan. 23, 2024 /PRNewswire/ -- Healthgrades , the #1 site Americans use to find a doctor or hospital, today announced the recipients of the 2024 America's Best Hospitals Awards and State Rankings.
  • To determine the top 250 U.S. hospitals, Healthgrades evaluated clinical performance for approximately 4,500 hospitals across more than 30 common procedures and conditions.
  • In tandem with this national recognition, Healthgrades measured the hospitals across 18 key specialty areas* to identify the highest-ranking hospitals in 32 eligible states.
  • **
    The complete list of 2024 America's Best Hospitals and its detailed methodology are available on Healthgrades.

CellVax Submits IND Application for Individualized Cell-based Immunotherapy FK-PC101 with Support of Theragent

Retrieved on: 
Wednesday, December 20, 2023

CellVax and Theragent partnered in November of 2022, with CellVax seeking clearance to proceed with their Phase II adaptive design clinical trial.

Key Points: 
  • CellVax and Theragent partnered in November of 2022, with CellVax seeking clearance to proceed with their Phase II adaptive design clinical trial.
  • Fernando Kreutz, CEO at CellVax, stated, "We are proud and excited for this IND submission of FK-PC101.
  • Theragent provided contract services to CellVax, including process optimization, assay development, and regulatory affairs support while preparing the IND package for this novel compound.
  • "We are proud to support CellVax and nurture this important immunotherapy on its clinical journey," continued Jeff Masten, Theragent's Chief Operating Officer.

Real-World Data Presented at SUO 2023 Show that Veracyte’s Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress

Retrieved on: 
Friday, December 1, 2023

Assessment with the Decipher Prostate Genomic Classifier and biological insights from the Decipher Genomic Resource for Intelligent Discovery (GRID) research tool indicated that Decipher scoring was associated with grade progression, but not volume progression, of prostate cancer.

Key Points: 
  • Assessment with the Decipher Prostate Genomic Classifier and biological insights from the Decipher Genomic Resource for Intelligent Discovery (GRID) research tool indicated that Decipher scoring was associated with grade progression, but not volume progression, of prostate cancer.
  • “We developed the Decipher Prostate Genomic Classifier to provide actionable information that helps guide patient care,” said Elai Davicioni, Ph.D., Veracyte’s medical director for Urology.
  • “The data presented at SUO 2023 show how users of our test, conducting prospective research on their own patients, affirm the utility of Decipher in real-world settings.
  • We are very grateful for the work conducted by these clinician-scientists on behalf of the entire prostate cancer research community.”

Veracyte Announces that Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict Treatment Response in Recurrent Prostate Cancer

Retrieved on: 
Tuesday, August 22, 2023

(Nasdaq: VCYT) announced that new data published in JCO Precision Oncology suggest that gene expression signatures derived from the company’s Decipher Genomics Resource for Intelligent Discovery (GRID) database may help advance understanding of the genomic drivers impacting patient response to treatment for recurrent prostate cancer.

Key Points: 
  • (Nasdaq: VCYT) announced that new data published in JCO Precision Oncology suggest that gene expression signatures derived from the company’s Decipher Genomics Resource for Intelligent Discovery (GRID) database may help advance understanding of the genomic drivers impacting patient response to treatment for recurrent prostate cancer.
  • The findings, from the Phase 2 STREAM study, suggest the potential to use transcriptomic signatures to identify patients in this setting who may benefit from more intensive salvage therapy as well as those who may need alternative care such as chemotherapy.
  • A previous publication demonstrated that 51% of men remained free of disease at three years following treatment.
  • GRID-derived information is available on a Research Use Only basis.

Study Published in JNCI Cancer Spectrum Demonstrates Real-World Utility of Veracyte’s Decipher Prostate Genomic Classifier in Prostate Cancer Treatment

Retrieved on: 
Tuesday, August 1, 2023

(Nasdaq: VCYT) announced the publication of a large, real-world study reinforcing the Decipher Prostate Genomic Classifier’s ability to guide personalized treatment approaches for men with prostate cancer.

Key Points: 
  • (Nasdaq: VCYT) announced the publication of a large, real-world study reinforcing the Decipher Prostate Genomic Classifier’s ability to guide personalized treatment approaches for men with prostate cancer.
  • The study utilized data from the first linkage of prostate cancer cases reported by central cancer registries participating in the Surveillance, Epidemiology, and End Results (SEER) Program, with Decipher test results.
  • The Decipher Prostate test molecularly assesses the likelihood of a patient’s cancer metastasizing within the next five years.
  • "This study is further evidence that the Decipher Prostate test provides valuable clinical information to physicians and their patients with prostate cancer.

TULSA Procedure Featured in the Scientific Program at the American Urological Association 2023 Annual Meeting

Retrieved on: 
Monday, May 1, 2023

TORONTO, May 01, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced the presentation of four studies of the Transurethral Ultrasound Ablation (“TULSA”) procedure at the American Urological Association (“AUA”) 2023 Annual Meeting, which took place from April 28 - May 1, 2023 at McCormick Place in Chicago, Illinois.

Key Points: 
  • The data demonstrate that both oncological control and functional outcomes are durable to four years after treatment with TULSA.
  • Urinary function was durable over the four-year follow-up period, with 99% of patients preserving urinary continence (≤1 pad/day) and 94% remaining completely pad-free.
  • At follow-up, oncological success was 88%, with 85% of men with LUTS before treatment experiencing relief after treatment with TULSA.
  • There were two Grade 4 complications - one after HIFU ablation and one after RALP - but none after TULSA.